Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants
- PMID: 22382151
- PMCID: PMC3476702
- DOI: 10.1097/QAD.0b013e328352d135
Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants
Abstract
Objective: To evaluate the association of tenofovir disoproxil fumarate (TDF) use during pregnancy with early growth parameters in HIV-exposed, uninfected (HEU) infants.
Design: US-based prospective cohort study of HEU children to examine potential adverse effects of prenatal TDF exposure.
Methods: We evaluated the association of maternal TDF use during pregnancy with small for gestational age (SGA); low birth weight (LBW, <2.5 kg); weight-for-age z-scores (WAZ), length-for-age z-scores (LAZ), and head circumference-for-age (HCAZ) z-scores at newborn visit; and LAZ, HCAZ, and WAZ at age 1 year. Logistic regression models for LBW and SGA were fit, adjusting for maternal and sociodemographic factors. Adjusted linear regression models were used to evaluate LAZ, WAZ, and HCAZ by TDF exposure.
Results: Of 2029 enrolled children with maternal antiretroviral information, TDF was used by 449 (21%) HIV-infected mothers, increasing from 14% in 2003 to 43% in 2010. There was no difference between those exposed to combination regimens with vs. without TDF for SGA, LBW, and newborn LAZ and HCAZ. However, at age 1 year, infants exposed to combination regimens with TDF had significantly lower adjusted mean LAZ and HCAZ than those without TDF (LAZ: -0.17 vs. -0.03, P=0.04; HCAZ: 0.17 vs. 0.42, P=0.02).
Conclusion: TDF use during pregnancy was not associated with increased risk for LBW or SGA. The slightly lower mean LAZ and HCAZ observed at age 1 year in TDF-exposed infants are of uncertain significance but underscore the need for additional studies of growth outcomes after TDF use during pregnancy.
Conflict of interest statement
All authors declare no conflict of interest.
Comment in
-
Does maternal use of tenofovir during pregnancy affect growth of HIV-exposed uninfected infants?AIDS. 2012 Jun 1;26(9):1167-9. doi: 10.1097/QAD.0b013e3283536b5e. AIDS. 2012. PMID: 22592070 No abstract available.
Similar articles
-
Maternal Tenofovir Disoproxil Fumarate Use in Pregnancy and Growth Outcomes among HIV-Exposed Uninfected Infants in Kenya.Infect Dis Obstet Gynecol. 2015;2015:276851. doi: 10.1155/2015/276851. Epub 2015 Dec 28. Infect Dis Obstet Gynecol. 2015. PMID: 26823647 Free PMC article.
-
Tenofovir exposure in utero and linear growth in HIV-exposed, uninfected infants.AIDS. 2017 Jan 2;31(1):97-104. doi: 10.1097/QAD.0000000000001302. AIDS. 2017. PMID: 27898591 Free PMC article.
-
Does maternal use of tenofovir during pregnancy affect growth of HIV-exposed uninfected infants?AIDS. 2012 Jun 1;26(9):1167-9. doi: 10.1097/QAD.0b013e3283536b5e. AIDS. 2012. PMID: 22592070 No abstract available.
-
Safety of tenofovir during pregnancy for the mother and fetus: a systematic review.Clin Infect Dis. 2013 Dec;57(12):1773-81. doi: 10.1093/cid/cit601. Epub 2013 Sep 17. Clin Infect Dis. 2013. PMID: 24046310 Review.
-
Safety of Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Regimens in Pregnancy for HIV-Infected Women and Their Infants: A Systematic Review and Meta-Analysis.J Acquir Immune Defic Syndr. 2017 Sep 1;76(1):1-12. doi: 10.1097/QAI.0000000000001359. J Acquir Immune Defic Syndr. 2017. PMID: 28291053 Free PMC article. Review.
Cited by
-
Fetal growth assessed via ultrasound in relation to maternal HIV infection status and antiretroviral regimens.AIDS. 2024 Mar 15;38(4):567-577. doi: 10.1097/QAD.0000000000003796. Epub 2023 Nov 21. AIDS. 2024. PMID: 37991521
-
Pregnancy outcomes following self-reported and objective-measured exposure to oral preexposure prophylaxis in South Africa.AIDS. 2024 Jan 1;38(1):75-83. doi: 10.1097/QAD.0000000000003729. Epub 2023 Nov 22. AIDS. 2024. PMID: 37720980 Free PMC article.
-
Maintenance darunavir/ritonavir monotherapy to prevent perinatal HIV transmission, ANRS-MIE 168 MONOGEST study.J Antimicrob Chemother. 2023 Jul 5;78(7):1711-1722. doi: 10.1093/jac/dkad161. J Antimicrob Chemother. 2023. PMID: 37248782 Free PMC article. Clinical Trial.
-
Antiretroviral Options and Treatment Decisions During Pregnancy.Paediatr Drugs. 2023 May;25(3):267-282. doi: 10.1007/s40272-023-00559-w. Epub 2023 Feb 2. Paediatr Drugs. 2023. PMID: 36729360 Review.
-
No Difference in Growth Outcomes up to 24 Months of Age by Duration of Exposure to Maternal Antiretroviral Therapy Among Children Who Are HIV-Exposed and Uninfected in Malawi.Front Pediatr. 2022 Jun 20;10:882468. doi: 10.3389/fped.2022.882468. eCollection 2022. Front Pediatr. 2022. PMID: 35795331 Free PMC article.
References
-
- Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents – October 14, 2011. [Accessed November 2, 2011.]; http://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?GuidelineID=7&Cl....
-
- Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States - September 14, 2011. [Accessed November 2, 2011.]; http://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?GuidelineID=9&Cl.... - PubMed
-
- Tarantal A, Castillo A, Ekert J, Bischofberger N, Martin R. Fetal and Maternal Outcome After Administration of Tenofovir to Gravid Rhesus Monkeys (Macaca mulatta) J Acquir Immune Defic Syndr. 2002;29(3):207. - PubMed
-
- Van Rompay K, Durand-Gasselin L, Brignolo L, Ray A, Abel K, Cihlar T, et al. Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics, biological and virological effects. Antimicrob Agents Chemother. 2008;52(9):3144–60. - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical